| Entry |
|
|---|
| Name |
Emtricitabine and tenofovir alafenamide;
Descovy (TN)
|
|---|
| Product |
|
|---|
| Component |
Emtricitabine [DR: D01199], (Tenofovir alafenamide fumarate [DR: D10605] | Tenofovir alafenamide [DR: D10428])
|
|---|
| Remark |
| Therapeutic category: | 6250 |
|
|---|
| Efficacy |
Antiviral |
|---|
| Disease |
|
|---|
| Comment |
Tenofovir alafenamide is a substrate of cathepsin A, CYP3A and P-gp.
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR17 Emtricitabine and tenofoviralafenamide
D10835 Emtricitabine and tenofovir alafenamide <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Other
Emtricitabine/ Tenofovir Alafenamide Fumarate
D10835 Emtricitabine and tenofovir alafenamide
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10835 Emtricitabine and tenofovir alafenamide
Antiinfectives [br08350.html]
Antivirals
D10835
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10835
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
